ERBB2 and neoplasm: Tumor uptake of 111In-DOTA-trastuzumab in MDA-MB-231, BT-20, MDA-MB-361, or SKOV-3 xenografts with increasing HER2 density was 4.7 ± 0.6%, 5.5 ± 0.7%, 4.0 ± 0.9%, and 5.4 ± 0.4% i.d./g.